6 days Ago By Defense World Staff
Renaissance Technologies LLC raised its holdings in Pulmonx Co. ( NASDAQ:LUNG – Free Report ) by 38.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The fund owned 220,510 shares of the company’s stock after acquiring an additional 61,500 shares during the quarter. Renaissance Technologies LLC owned 0.56% of Pulmonx worth $1,497,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its holdings in Pulmonx by 1.8% during the third quarter.
Barclays PLC now owns 94,109 shares of the company’s stock worth $780,000 after buying an additional 1,679 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pulmonx by 1.3% in the 3rd quarter.
Geode Capital Management LLC now owns 892,786 shares of the company’s stock worth $7,403,000 after acquiring an additional 11,151 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Pulmonx by 2.
3% during the third quarter. Franklin Resources Inc. now owns 700,389 shares of the company’s stock valued at $5,806,000 after purchasing an additional 15,570 shares during the last quarter.
272 Capital LP acquired a new position in shares of Pulmonx in the 3rd quarter valued at $48,000. Finally, JPMorgan Chase & Co. increased its stake in Pulmonx by 2.
4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock worth $8,750,000 after purchasing an additional 25,002 shares in the last quarter.
Institutional investors and hedge funds own 91.04% of the company’s stock. Analyst Ratings Changes A number of research firms have commented on LUNG.
Citigroup started coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a “buy” rating for the company. Morgan Stanley began coverage on shares of Pulmonx in a research note on Monday, March 10th.
They issued an “equal weight” rating for the company. Jefferies Financial Group assumed coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating for the company.
Finally, D. Boral Capital started coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating and a $17.
00 price target on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.
75. Insider Buying and Selling In other news, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Thursday, March 20th.
The shares were sold at an average price of $7.85, for a total value of $157,000.00.
Following the completion of the sale, the director now directly owns 991,974 shares in the company, valued at approximately $7,786,995.90. The trade was a 1.
98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, insider Geoffrey Beran Rose sold 5,779 shares of the firm’s stock in a transaction on Monday, March 3rd.
The shares were sold at an average price of $7.13, for a total transaction of $41,204.27.
Following the completion of the transaction, the insider now owns 285,278 shares in the company, valued at $2,034,032.14. The trade was a 1.
99 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last three months, insiders sold 145,660 shares of company stock worth $1,128,484.
Corporate insiders own 6.80% of the company’s stock. Pulmonx Stock Performance Shares of LUNG stock opened at $5.
19 on Tuesday. Pulmonx Co. has a fifty-two week low of $4.
15 and a fifty-two week high of $10.01. The stock’s 50-day moving average is $6.
78 and its two-hundred day moving average is $6.59. The company has a debt-to-equity ratio of 0.
40, a current ratio of 7.70 and a quick ratio of 6.77.
The firm has a market cap of $208.88 million, a P/E ratio of -3.60 and a beta of 0.
61. Pulmonx ( NASDAQ:LUNG – Get Free Report ) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.
33) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12.
The firm had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million.
Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%.
Analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.
Pulmonx Profile ( Free Report ) Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. See Also Five stocks we like better than Pulmonx Consumer Staples Stocks, Explained Best Defense Stocks in 2025.
.. So Far How to Calculate Return on Investment (ROI) Alphabet Rebounds After Strong Earnings and Buyback Announcement What is a Dividend King? Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.
com's FREE daily email newsletter ..
